Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results announced for the three months ended June 30, 2026.
Atea Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results announced for the three months ended June 30, 2026
- Detailed financial figures and management commentary available in Exhibit 99.1
- Results release provides the latest update on Atea’s financial condition and operating performance
Item EX-99.1 · Exhibit EX-99.1
- C-BEYOND met non-inferiority: BEM/RZR SVR 93.9% vs 94.8% for SOF/VEL in 905 patients
- Eight-week BEM/RZR achieved 93.5% SVR in non-cirrhotic patients vs 94.6% for 12-week SOF/VEL
- C-FORWARD enrolled over 880 patients across 17 countries, with topline results expected early Q1 2027
- Potential US NDA submission targeted for Q2 2027, making C-FORWARD the next major regulatory catalyst
- Cash and investments declined to $219.5M from $301.8M, while six-month net loss rose to $78.4M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atea Pharmaceuticals, Inc. 8-K filings
Get the next AVIR 8-K as it lands
Follow AVIR for push alerts, or ask the research agent what this filing means.